(Q41708746)

7 October 2017

title

Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer (English)

1 reference

7 October 2017

Fadi S Farhat

1

1 reference

7 October 2017

Marwan G Ghosn

series ordinal

2

1 reference

7 October 2017

Joseph G Kattan

series ordinal

3

1 reference

7 October 2017

publication date

30 May 2015

1 reference

Cancer Chemotherapy and Pharmacology

7 October 2017

published in

1 reference

7 October 2017

volume

76

1 reference

7 October 2017

issue

2

1 reference

7 October 2017

page(s)

235-242

1 reference

7 October 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

New treatment approaches for lung cancer and impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Chemotherapy for advanced non-small cell lung cancer: standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung can

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Oral versus intravenous vinorelbine: clinical safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2785-9

10.1007/S00280-015-2785-9

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wjuo7tinqjdinazjrwm6rz55ty

mapped directly with Wikidata item

30 July 2022

based on heuristic

Dimensions Publication ID

1051958771

0 references

Fatcat ID

release_wjuo7tinqjdinazjrwm6rz55ty

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wjuo7tinqjdinazjrwm6rz55ty

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/wjuo7tinqjdinazjrwm6rz55ty

1 reference